TriFoil Imaging Revenue and Competitors
Estimated Revenue & Valuation
- TriFoil Imaging's estimated annual revenue is currently $1.6M per year.
- TriFoil Imaging's estimated revenue per employee is $155,000
Employee Data
- TriFoil Imaging has 10 Employees.
- TriFoil Imaging grew their employee count by -23% last year.
TriFoil Imaging's People
Name | Title | Email/Phone |
---|
TriFoil Imaging Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $5.4M | 70 | -8% | $53M | N/A |
#2 | $32.4M | 167 | -26% | $110M | N/A |
#3 | $0.9M | 6 | 0% | N/A | N/A |
#4 | $2.8M | 18 | 13% | N/A | N/A |
#5 | $0.8M | 5 | -50% | N/A | N/A |
#6 | $0.8M | 10 | 0% | N/A | N/A |
#7 | $14M | 90 | -12% | N/A | N/A |
#8 | $0.4M | 336 | 10% | $236.7M | N/A |
#9 | $4.8M | 62 | -74% | $160M | N/A |
#10 | $3.7M | 24 | -8% | N/A | N/A |
What Is TriFoil Imaging?
TriFoil Imaging, based in Chatsworth, CA, is a market and technological leader in the preclinical imaging industry. Formed in 2013, TriFoil Imaging originates from the merging of Bioscan Inc. and Gamma Medica. Offering top notch service for current and legacy instruments, as well as applications-based support to customers worldwide, TriFoil Imaging is dedicated to and focused on helping customers work towards the next breakthroughs in medicine and biology. TriFoil Imaging offers the InSyTe FLECT/CT, a preclinical optical imaging platform that combines the strengths of fluorescence tomography with X-ray CT. The InSyTe FLECT/CT performs 360° fluorescence and CT data acquisition, an industry-first, for true 3D tomographic imaging.
keywords:N/AN/A
Total Funding
10
Number of Employees
$1.6M
Revenue (est)
-23%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $1M | 11 | 22% | N/A |
#2 | $1.6M | 11 | -31% | N/A |
#3 | $1.5M | 12 | -40% | N/A |
#4 | $2M | 14 | 27% | N/A |
#5 | $1.3M | 15 | 7% | N/A |